Vir Biotechnology (VIR) Expected to Announce Earnings on Wednesday

Vir Biotechnology (NASDAQ:VIR) will likely be posting its quarterly earnings results after the market closes on Wednesday, February 26th. Analysts expect Vir Biotechnology to post earnings of ($0.85) per share and revenue of $8.14 million for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Vir Biotechnology Trading Down 2.3 %

VIR opened at $9.57 on Monday. The stock’s 50-day moving average price is $9.31 and its 200 day moving average price is $8.48. Vir Biotechnology has a 12-month low of $6.56 and a 12-month high of $14.45. The firm has a market cap of $1.32 billion, a price-to-earnings ratio of -2.44 and a beta of 0.64.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Barclays decreased their target price on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Morgan Stanley upgraded Vir Biotechnology from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $10.00 to $20.00 in a report on Thursday, January 9th. JPMorgan Chase & Co. upped their price target on Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a report on Thursday, January 9th. Leerink Partners upped their price target on Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Finally, HC Wainwright restated a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a report on Friday, January 31st. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $34.83.

Insider Activity

In other news, Director Vicki L. Sato sold 10,960 shares of the stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total value of $137,219.20. Following the transaction, the director now owns 1,312,391 shares in the company, valued at approximately $16,431,135.32. This represents a 0.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director George A. Scangos sold 10,964 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.81, for a total value of $107,556.84. Following the completion of the transaction, the director now owns 708,295 shares in the company, valued at approximately $6,948,373.95. The trade was a 1.52 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,562 shares of company stock worth $259,693. 15.60% of the stock is currently owned by insiders.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).